Albert Beraldo

Telesta Therapeutics, Inc. is a biotechnology company, which focuses on the licensing/acquisition and development of transformational therapeutics for the treatment of serious human diseases, such as cancer, immune diseases, and targeted rare diseases. The company was founded by Graeme McRae in 1979 and is headquartered in Pointe-Claire, Canada.

Bioniche Pharma Group Ltd. is a specialty pharmaceutical company involved primarily in the development, manufacturing, and marketing of sterile injectable products. The company sells a number of non-branded products in the U.S. market for which it has received approved Abbreviated New Drug Applications. It also sells its branded product Suplasyn in 30 countries globally. The firm's products are sold to both the primary care and hospital markets in the U.S., Canada, and Europe. The company was founded in 2000 and is headquartered in Casla, Ireland.

Alveda Pharmaceuticals, Inc. sells and distributes pharmaceuticals and medical devices. Its products are available in different sizes and formats including glass vials, ampoules, syringes, and polyampoules. The firm''s consulting services cover areas, such as, product development, warehousing and logistics, manufacturing, quality control testing and product analysis, and labeling and package development. It serves hospitals, buying groups, wholesalers, individual physicians, pharmacists, and patients. The company was founded in November 2006 and is headquartered in Toronto, Canada.

Medicenna Therapeutics, Inc. develops and commercializes therapeutics for the treatment of central nervous system and urological cancers. It also develops proprietary therapeutic cytokines called Superkines, Superkines is powerful immune-system modulators that have significant therapeutic potential for the treatment of many forms of cancer and selected other diseases. Superkines can be fused to tumor cell-killing payloads to form Medicenna's proprietary Empowered Cytokines (EC's). The firm's EC's are being developed for the targeted treatment of cancer and are potentially vastly superior alternatives to other targeted cancer therapies such as Antibody Drug Conjugates. The company was founded by Fahar Merchan and Rosemina Merchant in 2011 and is headquartered in Vancouver, CA.